13F Holdings
中文EN

XBIT XBiotech Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1626878 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-49.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-29.9%
ROA-29.0%
ROIC (approx.)-193.7%
Asset turnover—

Leverage & solvency

Liabilities / assets3.5%
Debt / equity0.00x
Current ratio39.51x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.94x
Accruals ratio-1.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue——$0$4.01M$18.39M
Cost of revenue——$0$651,000$5.82M
Gross profit——$0$3.36M$12.57M
R&D expense$47.39M$37.76M$32.85M$31.54M$28.27M
SG&A expense$8.29M$4.71M$4.66M$6.30M$9.39M
Operating income-$55.69M-$42.47M-$37.51M-$34.49M-$25.08M
Pretax income-$45.30M-$38.56M-$24.31M-$33.59M-$25.46M
Income tax$235,000-$32,000$244,000-$688,000-$8.04M
Net income-$45.54M-$38.53M-$24.56M-$32.90M-$17.41M
EBITDA-$54.00M-$40.73M-$35.81M-$31.88M-$22.43M
EPS (basic)-1.49-1.26-0.81-1.08-0.58
EPS (diluted)-1.49-1.26-0.81-1.08-0.58
Weighted avg. shares (diluted)30.49M30.46M30.44M30.44M30.04M
Balance sheet
Cash & equivalents$125.55M$172.68M$200.02M$157.31M$236.98M
Short-term investments——$0$60.17M$0
Receivables—$700,000$860,000$1.22M$0
Current assets$126.95M$174.57M$201.72M$219.84M$246.87M
PP&E, net$23.13M$24.53M$24.90M$26.26M$28.31M
Total assets$150.08M$199.09M$226.62M$246.10M$275.18M
Current liabilities$7.93M$15.11M$6.10M$4.07M$3.45M
Total liabilities$9.73M$16.82M$7.77M$5.70M$5.79M
Shareholders' equity$140.35M$182.27M$218.85M$240.40M$269.38M
Shares outstanding30.49M30.49M30.44M30.44M30.44M
Cash flow statement
Operating cash flow-$39.92M-$30.96M-$18.73M-$14.82M$69.44M
Capital expenditure$289,000$1.30M$362,000$585,000$3.52M
Free cash flow-$40.21M-$32.27M-$19.09M-$15.41M$65.92M
Investing cash flow-$289,000-$1.30M$61.50M-$63.89M-$3.52M
Financing cash flow-$10.25M$10.45M-$9,000$0-$67.01M
Depreciation & amortization$1.69M$1.75M$1.70M$2.61M$2.65M
Stock-based compensation$3.62M$1.75M$3.26M$5.06M$4.46M
Dividends paid———$0$75.00M
Share buybacks—$0$14,000$0—

Free plan shows the latest 5 periods; Pro shows all 13 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.